| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
PDE6D CK1α
PDE6D (phosphodiesterase 6D) and CK1alpha (casein kinase 1alpha). |
|---|---|
| ln Vitro |
In MOLT4 cells, TMX-4113 (compound 21; 1 μM; 4 h) exhibits a strong preference for PDE6D and CK1α degradation[1]. In MOLT4 cells, TMX-4113 (0 nM, 40 nM, 200 nM, 1µM; 4h) causes PDE6D degradation[1]. At a dosage of 40 nM, TMX-4113 (0 nM, 40 nM, 200 nM, 1µM; 4h) destroys more than 50% of CK1α in MM.1S cells[1].
In MOLT4 cells, TMX-4113 (compound 21; 1 microM; 4 h) exhibits a strong preference for degrading PDE6D and CK1alpha. At a concentration of 40 nM, it destroys more than 50% of CK1alpha in MM.1S cells. In MOLT4 cells, TMX-4113 (0-1 uM; 4h) induces PDE6D degradation in a dose-dependent manner. |
| ln Vivo |
No specific in vivo data has been identified for TMX-4113 in the available literature. However, as a targeted protein degrader, it is anticipated to be utilized in xenograft mouse models to evaluate its efficacy in degrading PDE6D and CK1alpha in a tumor microenvironment and to assess its potential anti-tumor activity in future cancer research studies.
|
| Enzyme Assay |
Western blot analysis is used to assess protein degradation. Cell Types: MOLT4 cells. Tested Concentrations: 1 microM. Incubation Duration: 4 h. Experimental Results: demonstrated a high degradation preference for PDE6D and CK1alpha. For dose-response, cells are treated with 0 nM, 40 nM, 200 nM, and 1 uM for 4 h.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MOLT4 cells Tested Concentrations: 1 μM Incubation Duration: 4 h Experimental Results: demonstrated a high degradation preference for PDE6D and CK1α. Western Blot Analysis[1] Cell Types: MOLT4 cells Tested Concentrations: 0 nM, 40 nM, 200 nM, 1µM Incubation Duration: 4 h Experimental Results: Induced degradation of PDE6D. Cell-based assays are performed in MOLT4 and MM.1S cells. MOLT4 cells are treated with TMX-4113 at concentrations of 0 nM, 40 nM, 200 nM, and 1 uM for 4 hours, followed by Western blot analysis to detect PDE6D and CK1alpha protein levels. In MM.1S cells, degradation of CK1alpha is assessed at 40 nM. |
| ADME/Pharmacokinetics |
Physicochemical properties: Molecular Formula = C12H12N4O2S2, Molecular Weight = 308.38, LogP = 0.9, Hydrogen Bond Donor Count = 1, Hydrogen Bond Acceptor Count = 6. Appearance: Off-white to light yellow solid powder. Solubility: DMSO : 100 mg/mL (324.28 mM). Storage: Powder -20degC for 3 years, 4degC for 2 years; In solvent -80degC for 6 months, -20degC for 1 month. Shipping: Room temperature (stable for a few days during shipping).
|
| References | |
| Additional Infomation |
TMX-4113 (CAS#: 2766385-92-4) is a dual-target protein degrader. It functions by recruiting the ubiquitin-proteasome system to degrade its target proteins PDE6D and CK1alpha. This mechanism of action is distinct from traditional enzyme inhibition, as it leads to the permanent removal of the target protein rather than just blocking its activity. It is a valuable chemical probe for studying the biological functions of PDE6D and CK1alpha in cancer signaling pathways. Purity: ≥98%.
|
| Molecular Formula |
C12H12N4O2S2
|
|---|---|
| Molecular Weight |
308.379279136658
|
| Exact Mass |
308.04
|
| CAS # |
2766385-92-4
|
| PubChem CID |
162641721
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CSC1=CSC=C1C2=CN(N=N2)C3CCC(=O)NC3=O
|
| InChi Key |
YIIUEHDPOPLUBR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H12N4O2S2/c1-19-10-6-20-5-7(10)8-4-16(15-14-8)9-2-3-11(17)13-12(9)18/h4-6,9H,2-3H2,1H3,(H,13,17,18)
|
| Chemical Name |
3-[4-(4-methylsulfanylthiophen-3-yl)triazol-1-yl]piperidine-2,6-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (324.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2428 mL | 16.2138 mL | 32.4275 mL | |
| 5 mM | 0.6486 mL | 3.2428 mL | 6.4855 mL | |
| 10 mM | 0.3243 mL | 1.6214 mL | 3.2428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
